Showing 2371-2380 of 5644 results for "".
- NIH Researchers Develop First Stem Cell Model of Albinism to Study Related Eye Conditionshttps://modernod.com/news/nih-researchers-develop-first-stem-cell-model-of-albinism-to-study-related-eye-conditions/2480560/Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA). The model’s development is described in the January issue of the journal Stem Cell
- Regenxbio Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Deliveryhttps://modernod.com/news/regenxbio-announces-initiation-of-second-pivotal-trial-in-rgx-314-clinical-program-for-the-treatment-of-wet-amd-using-subretinal-delivery/2480556/Regenxbio announced the initiation of ASCENT, the second of two phase 3 pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in patients with wet age-related macular degeneration (AMD). ASCENT, the first trial to be initiated by Regenxbio under the e
- Ray Therapeutics Closes $6M Seed Financing to Advance Novel Optogenetics Platform to Treat Blinding Diseaseshttps://modernod.com/news/ray-therapeutics-closes-6m-seed-financing-to-advance-novel-optogenetics-platform-to-treat-blinding-diseases/2480549/Ray Therapeutics, a developer of optogenetic gene therapies for patients with blinding diseases, announced the closing of a $6 million seed financing round, led by 4BIO Capital. The funding will be used to advance its optogenetic therapy, Ray-001, into clinical trials in retinitis
- Gentex Announces Partnership With eSight To Develop Next Generation Digital Eyewearhttps://modernod.com/news/gentex-announces-partnership-with-esight-to-develop-next-generation-digital-eyewear/2480538/Gentex announced that it is partnering with eSight, provider of vision enhancement technology, to develop and manufacture the next generation of mobile electronic eyewear designed to help people living with visual impairments. Terms of the d
- Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-in-china-screened-in-the-ongoing-ncx-470-denali-phase-3-trial-in-glaucoma/2480521/Nicox SA announced that the first patient has been screened in China in the ongoing Denali phase 3 clinical trial, opening the way for new drug application (NDA) submissions in both the United States and China for NCX 470, Nicox’s lead clinical product candidate in glaucoma. Denali, wh
- Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHONhttps://modernod.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/Luxembourg-based Mitotech SA announced that the FDA has granted orphan drug designation (ODD) for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare inherited condition that can lead to blin
- NIH Study Traces Molecular Link From Gene to Late-Onset Retinal Degenerationhttps://modernod.com/news/nih-study-traces-molecular-link-from-gene-to-late-onset-retinal-degeneration/2480510/Scientists have discovered that gene therapy and the diabetes drug metformin may be potential treatments for late-onset retinal degeneration (L-ORD), a rare, blinding eye disease. Researchers from the National Eye Institute (NEI), part of the National Institutes of Health, generated a “dise
- Novartis Announces Positive Year 2 Results of Phase 3 KESTREL Study of Beovu in Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-positive-results-from-year-2-of-the-phase-3-trial-of-beovu-in-diabetic-macular-edema/2480504/Novartis announced the first interpretable results from year 2 (week 100) of the phase 3 KESTREL study. KESTREL assessed the safety and efficacy of Beovu (brolucizumab) 6 mg in patients with visual impairment due to diabetic macular edema (DME). Results from year 2 confirmed the visual acuit
- Recently Approved Presbyopia Eye Drop Vuity Now Available in Pharmacieshttps://modernod.com/news/recently-approved-presbyopia-eye-drop-vuity-now-available-in-pharmacies/2480503/Allergan announced that Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the FDA to treat presbyopia, is now available by prescription in pharmacies nationwide. "We are pleased to be able to bring this first-of-its
- Study: Warning Signs of Sight Loss Could be Identified Before Vision Deteriorateshttps://modernod.com/news/study-warning-signs-of-sight-loss-could-be-identified-before-vision-deteriorates/2480502/A new study has shown that the signs of age related macular degeneration can set in earlier than previously thought – even before patients begin to lose their sight. The findings open the door for research into earlier treatment that could help slow down the onset of the condition the most